Literature DB >> 21120260

Reduced number of actinic keratoses with topical application of DNA repair enzyme creams.

Telia DeBoyes1, David Kouba, David Ozog, Edgar Fincher, Lauren Moy, Kathryn Iwata, Ronald Moy.   

Abstract

BACKGROUND: Actinic keratosis is regarded as a carcinoma in situ by some dermatologists and its incidence continues to rise. Exposure to ultraviolet (UV) radiation is considered to be an important risk factor for developing these pre-malignant lesions. DNA repair enzymes have been shown to reverse sun-damage, resulting in reduced rates of actinic keratoses and non-melanoma skin cancers in specific patient populations.
METHODS: Seventeen patients were evaluated for differences in actinic keratoses following topical application of T4N5 liposome lotion over 48 weeks.
RESULTS: Compared to baseline, a statistically significant reduction in the number of actinic keratoses was seen following the treatment period. DISCUSSION: This study suggests that DNA repair enzyme creams effectively reduce the number of actinic keratoses in normal individuals with moderate-to-severe photodamaged skin.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21120260

Source DB:  PubMed          Journal:  J Drugs Dermatol        ISSN: 1545-9616            Impact factor:   2.114


  3 in total

Review 1.  [Sunscreens of the future: challenges and opportunities].

Authors:  Peter Wolf; Jean Krutmann
Journal:  Hautarzt       Date:  2022-03-08       Impact factor: 0.751

2.  Six critical questions for DNA repair enzymes in skincare products: a review in dialog.

Authors:  Daniel B Yarosh; Amanda Rosenthal; Ronald Moy
Journal:  Clin Cosmet Investig Dermatol       Date:  2019-08-29

3.  AKASI and Near-Infrared Spectroscopy in the combined effectiveness evaluation of an actinic keratoses preventive product in immunocompetent and immunocompromised patients.

Authors:  Federica Veronese; Silvia Seoni; Vanessa Tarantino; Matteo Buttafava; Chiara Airoldi; Kristen M Meiburger; Elisa Zavattaro; Paola Savoia
Journal:  Front Med (Lausanne)       Date:  2022-09-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.